Status: Recruiting
Drug Eluting Stenting and Aggressive Medical Treatment for Preventing Recurrent Stroke in Intracranial Atherosclerotic Disease Trial
The aim of DREAM-PRIDE is to evaluate whether implantation of drug-eluting stent (DES) combined with aggressive medical treatment is more efficacious in prevention of 1-year stroke recurrence than standard medical treatment alone for symptomatic intracranial atherosclerotic disease.
Participants needed: 792
Trial details
Age: 18-85Biological sex: AllType: InterventionalSponsor: Beijing Tiantan HospitalUpdated: Dec 27, 2024Locations: 18
Eligibility criteria
Age from 18 to 85 years [+5]
Ischemic stroke occurred within 7 days before enrolment [+22]